Share on StockTwits

Eli Lilly and (NYSE:LLY) will release its Q214 earnings data on Thursday, July 24th. Analysts expect Eli Lilly and to post earnings of $0.65 per share and revenue of $4.88 billion for the quarter.

Shares of Eli Lilly and (NYSE:LLY) opened at 63.72 on Wednesday. Eli Lilly and has a 52 week low of $47.53 and a 52 week high of $64.15. The stock’s 50-day moving average is $61.45 and its 200-day moving average is $58.37. The company has a market cap of $68.352 billion and a P/E ratio of 17.79.

The company also recently announced a quarterly dividend, which is scheduled for Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $0.49 per share. This represents a $1.96 annualized dividend and a dividend yield of 3.08%. The ex-dividend date of this dividend is Wednesday, August 13th.

A number of research firms have recently commented on LLY. Analysts at Jefferies Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Monday, July 14th. They now have a $65.00 price target on the stock, up previously from $60.00. On the ratings front, analysts at Barclays upgraded shares of Eli Lilly and from an “underweight” rating to an “equal weight” rating in a research note on Wednesday, July 2nd. They now have a $63.00 price target on the stock, up previously from $51.00. Finally, analysts at Morgan Stanley reiterated an “underweight” rating on shares of Eli Lilly and in a research note on Monday, June 2nd. They now have a $48.00 price target on the stock. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $61.77.

Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.